Monopar doses first patient in Phase 1 MNPR-101-Zr trial; favorable safety and biodistribution data

Monopar Therapeutics

First patient dosed in open-label Phase 1 imaging trial of MNPR-101-Zr; well-tolerated with no serious adverse reactions.
Red bone marrow radiation dose ~14 mGy, roughly 150 times below the accepted limit of 2-3 Gy.
No unanticipated or excessive uptake in critical organs; biodistribution aligns with preclinical data.
Initial patient has metastatic cancer not known for high uPAR expression; study to include high-uPAR cancers.
COO Andrew Cittadine: data increases confidence to advance Phase 1 and prepare therapeutic study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.